Tulynode

Tulynode Biosciences is a private San Diego biotech developing an extracorporeal immune-oncology cell therapy approach centered on its Immuno-Pod platform. The company aims to activate a patient’s own autologous immune cells against that individual’s tumor in a closed-circuit system, with the goal of generating tumor-specific anti-cancer responses without complex ex vivo cell manipulation. Publicly available information indicates the company has patented methods for activating immune cells using an immune-modulating chamber that incorporates tumor and stromal components. Tulynode appears to remain a small, active private company, although its public web presence is limited and much of the historical detail comes from older licensing and patent records. The company also appears to be operating under or alongside the name Tulynode Therapeutics in more recent local business records.